| Yolanda Annetta Slaughter, DDS, MPH | |
|
1301 Atlantic Ave, Atlantic City, NJ 08401-7247 | |
| (609) 572-0000 | |
| (609) 572-0039 |
| Full Name | Yolanda Annetta Slaughter |
|---|---|
| Gender | Female |
| Speciality | Dentist |
| Location | 1301 Atlantic Ave, Atlantic City, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699085035 | NPI | - | NPPES |
| 1025414230002 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | DS031518L (Pennsylvania) | Secondary |
| 122300000X | Dentist | 22DI02853300 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Yolanda Annetta Slaughter, DDS, MPH 1 N White Horse Pike, Hammonton, NJ 08037-1875 Ph: () - | Yolanda Annetta Slaughter, DDS, MPH 1301 Atlantic Ave, Atlantic City, NJ 08401-7247 Ph: (609) 572-0000 |
News Archive
A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA.
Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced U.S. Patent Number 8,084,425 has been issued for MANF entitled, Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof.
Exposure to the phytoestrogen genistein prior to conception may adversely affect female fertility and pregnancy outcomes, depending on the dosage and duration of exposure, a new study in mice suggests.
ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.
The Zona Plus isometric handgrip device ("Zona Plus") which combines personalized technology and an easy-to-follow 12 minutes per day, five days per week routine for patients with high blood pressure is now available in Canada.
› Verified 6 days ago
Magnolia M Pelaez, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 1301 Atlantic Ave, Atlantic City, NJ 08401 Phone: 609-572-0000 Fax: 609-567-0039 | |
Dr. Murray William Borman, DMD Dentist Medicare: Medicare Enrolled Practice Location: 4123 Atlantic Ave, Atlantic City, NJ 08401 Phone: 609-344-2434 | |
Dr. Phan K. Huynh, DMD Dentist Medicare: Medicare Enrolled Practice Location: 1 S New York Ave, Suite 101, Atlantic City, NJ 08401 Phone: 609-345-1155 Fax: 609-345-5323 | |
Robert E Hill, DMD Dentist Medicare: Medicare Enrolled Practice Location: 1301 Atlantic Ave, Atlantic City, NJ 08401 Phone: 609-572-0000 Fax: 609-572-0039 | |
Dr. Joel G. Weiss, D.M.D Dentist Medicare: Medicare Enrolled Practice Location: 3822 Ventnor Ave, Atlantic City, NJ 08401 Phone: 609-653-1111 Fax: 609-653-6247 | |
Seemeen S Sheikh, D.M.D Dentist Medicare: Not Enrolled in Medicare Practice Location: 1325 Baltic Ave, Atlantic City, NJ 08401 Phone: 609-441-0950 |